LV12315B - Risperidona pamoāts - Google Patents

Risperidona pamoāts Download PDF

Info

Publication number
LV12315B
LV12315B LVP-99-32A LV990032A LV12315B LV 12315 B LV12315 B LV 12315B LV 990032 A LV990032 A LV 990032A LV 12315 B LV12315 B LV 12315B
Authority
LV
Latvia
Prior art keywords
risperidone
pamoate
composition
composition according
compound according
Prior art date
Application number
LVP-99-32A
Other languages
English (en)
Other versions
LV12315A (lv
Inventor
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of LV12315A publication Critical patent/LV12315A/lv
Publication of LV12315B publication Critical patent/LV12315B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Claims (9)

  1. LV 12315 IZGUDROJUMA FORMULA 1. Risperidona pamoāts pievienotas skābes sāls formā ar formulu
    15
  2. 2. Kompozīcija, kas satur farmaceitiski saderīgu nesēju un kā aktīvo ingredientu savienojuma saskaņā ar 1. punktu farmaceitiski efektīvu daudzumu.
  3. 3. Kompozīcija saskaņā ar 2. punktu injicējamā dozēšanas formā.
  4. 4. Kompozīcija saskaņā ar 3. punktu, kas ir ūdens suspensijas formā.
  5. 5. Kompozīcija saskaņā ar 4. punktu, kas bez tam satur benzilspirtu, 25 sorbitānesteri un ūdeni.
  6. 6. Kompozīcija saskaņā ar 5. punktu, kas bez tam satur celulozes atvasinājumu.
  7. 7. Metode kompozīcijas saskaņā ar jebkuru no 2. līdz 5. punktam iegūšanai, kas atšķiras ar to, ka savienojuma saskaņā ar 1. punktu farmaceitiski efektīvs daudzums tiek rūpīgi sajaukts ar farmaceitiski saderīgu nesēju.
  8. 8. Savienojums saskaņā ar 1. punktu izmantošanai par medikamentu. 35 2
  9. 9. Metode savienojuma saskaņā ar 1. punktu iegūšanai, kas atšķiras ar 3-[2-[4-(6-fl uor-1,2-benzizoksazol-3-il)-1-piperidinil]etil]-6,7,8,9-tetrahidro-2-me-til-4H-pirido[1,2-a]pirimidīn-4-ona apstrādi ar pamoaskābi reakcijā inertā šķīdinātajā.
LVP-99-32A 1993-04-28 1999-02-24 Risperidona pamoāts LV12315B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93201216 1993-04-28

Publications (2)

Publication Number Publication Date
LV12315A LV12315A (lv) 1999-07-20
LV12315B true LV12315B (lv) 2000-03-20

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-32A LV12315B (lv) 1993-04-28 1999-02-24 Risperidona pamoāts

Country Status (32)

Country Link
US (2) US5612346A (lv)
EP (1) EP0697019B1 (lv)
JP (1) JP3478397B2 (lv)
KR (1) KR100307101B1 (lv)
CN (1) CN1041727C (lv)
AT (1) ATE163418T1 (lv)
AU (1) AU675136B2 (lv)
BG (1) BG62004B1 (lv)
CA (1) CA2160366C (lv)
CY (1) CY2107B1 (lv)
CZ (1) CZ286688B6 (lv)
DE (1) DE69408666T2 (lv)
DK (1) DK0697019T3 (lv)
ES (1) ES2113652T3 (lv)
FI (1) FI109125B (lv)
GR (1) GR3026028T3 (lv)
HK (1) HK1006059A1 (lv)
HU (1) HU218212B (lv)
IL (1) IL109448A (lv)
LV (1) LV12315B (lv)
NO (1) NO305083B1 (lv)
NZ (1) NZ266143A (lv)
PH (1) PH30476A (lv)
PL (1) PL182466B1 (lv)
RO (1) RO115955B1 (lv)
RU (1) RU2131428C1 (lv)
SG (1) SG47046A1 (lv)
SI (1) SI9420031B (lv)
SK (1) SK280589B6 (lv)
TW (1) TW376319B (lv)
WO (1) WO1994025460A1 (lv)
ZA (1) ZA942909B (lv)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CZ300725B6 (cs) * 1997-09-30 2009-07-29 Eli Lilly And Company 2-Methylthienbenzodiazepinová formulace
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EA002580B1 (ru) * 1998-09-30 2002-06-27 Эли Лилли Энд Компани Готовая препаративная форма 2-метил-тиено-бензодиазепина
JP2002529468A (ja) * 1998-11-12 2002-09-10 メルク エンド カムパニー インコーポレーテッド ＧＡＢＡ−Ａα−５逆活性薬の治療性多形およびそのパモエート組成物
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2003250472A1 (en) * 2002-08-23 2004-03-11 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
ES2315721T5 (es) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
ATE511512T1 (de) * 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
UA97286C2 (ru) * 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
ES2868353T3 (es) * 2007-12-19 2021-10-21 Janssen Pharmaceutica Nv Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción
RU2627469C2 (ru) 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
US9040695B2 (en) * 2011-04-26 2015-05-26 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
CA2867137C (en) * 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
AU2013245011B2 (en) 2012-04-04 2017-11-23 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
CN102659577B (zh) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 一种亚甲基双羟基萘酸的制备方法
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
NZ706067A (en) * 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
CA2943213C (en) 2014-03-20 2022-07-05 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
FI955166A (fi) 1995-10-27
SG47046A1 (en) 1998-03-20
TW376319B (en) 1999-12-11
HU9501934D0 (en) 1995-09-28
CZ270695A3 (en) 1996-01-17
NO954275L (no) 1995-10-26
ZA942909B (en) 1995-10-26
BG100094A (bg) 1996-05-31
CN1121719A (zh) 1996-05-01
EP0697019B1 (en) 1998-02-25
BG62004B1 (bg) 1998-12-30
IL109448A (en) 1997-03-18
ES2113652T3 (es) 1998-05-01
HU218212B (hu) 2000-06-28
CN1041727C (zh) 1999-01-20
SI9420031B (sl) 2002-08-31
IL109448A0 (en) 1994-07-31
FI955166A0 (fi) 1995-10-27
PH30476A (en) 1997-05-28
KR100307101B1 (ko) 2001-11-30
DE69408666D1 (de) 1998-04-02
US5723467A (en) 1998-03-03
FI109125B (fi) 2002-05-31
JP3478397B2 (ja) 2003-12-15
PL182466B1 (pl) 2002-01-31
SK280589B6 (sk) 2000-04-10
RU2131428C1 (ru) 1999-06-10
EP0697019A1 (en) 1996-02-21
LV12315A (lv) 1999-07-20
DK0697019T3 (da) 1998-09-28
NO305083B1 (no) 1999-03-29
HK1006059A1 (en) 1999-02-05
CA2160366C (en) 2006-06-06
WO1994025460A1 (en) 1994-11-10
PL311282A1 (en) 1996-02-05
CA2160366A1 (en) 1994-11-10
RO115955B1 (ro) 2000-08-30
NZ266143A (en) 1996-07-26
ATE163418T1 (de) 1998-03-15
NO954275D0 (no) 1995-10-26
US5612346A (en) 1997-03-18
CY2107B1 (en) 2002-04-26
AU6721694A (en) 1994-11-21
GR3026028T3 (en) 1998-04-30
AU675136B2 (en) 1997-01-23
CZ286688B6 (en) 2000-06-14
DE69408666T2 (de) 1998-06-18
SK131395A3 (en) 1996-06-05
SI9420031A (en) 1996-08-31
HUT72970A (en) 1996-06-28
JPH08509482A (ja) 1996-10-08

Similar Documents

Publication Publication Date Title
LV12315B (lv) Risperidona pamoāts
US4725691A (en) 2-[8-quinolinyl]-sulphinyl-1H-benzimidazole
PL188908B1 (pl) Nowe pochodne benzimidazolu i ich zastosowanie dowytwarzania leków do leczenia stanów alergicznych
US3399201A (en) Aminoalkyl-ethano-anthracenes
DE60112254T2 (de) Benzthiazolderivate die tnf und pde-iv hemmen
GB1561561A (en) Bis (i-phenoxyalkane carboxylic acids) and derivatives thereof process for their preparation and their use as medicaments
LV10868B (en) Oxadiazolyl-alkyl-purine derivatives
EP0089028B1 (de) Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung
JPH0568476B2 (lv)
RU2459824C2 (ru) Новые соединения для лечения психических расстройств, их получение и применение
JPS5874678A (ja) チアキサンテン誘導体のアルフア異性体のエステルと該エステルの酸附加塩とを製造し且つ精製する方法
GB2081708A (en) Novel derivatives of (1-benzyl-1h-indazol-3-yl) oxyacetic acid and pharmaceutical composition containing it
US3632653A (en) Ethano-anthracenes
US5883255A (en) Substituted indolizino 1,2-b!quinolinones
US3489799A (en) Ethano-anthracenes
JPS6222992B2 (lv)
US4798832A (en) Pyrido[1,2-a]pyrimidine compounds, corresponding intermediates and use as SRS-A antagonists
CZ380596A3 (en) Salts of 2-(2,6-dichlorophenyl)amino)phenylacetoxyacetic acid with cations of organic bases, process of their preparation, pharmaceutical compositions containing thereof and their use
IE42161B1 (en) Pyrano-quinoline carboxylic acids,processes for their preparation and their use as pharmaceutical agents
AU614757B2 (en) Hydroquinonylphenyl butyric acid amide derivative
JPH0559053A (ja) インドールアルカロイド化合物
JP3029870B2 (ja) キノリン誘導体
KR800001144B1 (ko) 2-(4-페닐-4-시아노부틸)-1,2,3,4-테트라하이드로-5(H)-피리도-[4,3-b]-인돌의 제조방법
JPH09124608A (ja) シクロプロパン誘導体及びそれを含有する抗ウイルス剤